| Forum: Forum Forschung Haarausfall |
|---|
| Thema: ??? |
|---|
|
| Thema: Neuigkeiten im April |
|---|
|
| Thema: Was haltet ihr von dem? |
|---|
|
| Thema: Artikel zur HA-Genforschung |
|---|
|
| Thema: Forscher reprogrammieren Körperzellen ohne Krebs |
|---|
|
| Thema: P-cadherin is a p63 target gene with a crucial role in the developing human limb bud and hair follic |
|---|
| P-cadherin is a p63 target gene with a crucial role in the developing human limb bud and hair follic [Beitrag #2422] |
Sun, 20 January 2008 12:35 |
 |
 pietrasch
Beiträge: 48
Registriert: December 2005 |
Member |
|
|
P-cadherin is a p63 target gene with a crucial role in the developing human limb bud and hair follicle.
Shimomura Y, Wajid M, Shapiro L, Christiano AM.
P-cadherin is a member of the classical cadherin family that forms the transmembrane core of adherens junctions. Recently, mutations in the P-cadherin gene (CDH3) have been shown to cause two inherited diseases in humans: hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome). The common features of both diseases are sparse hair and macular dystrophy of the retina, while only EEM syndrome shows the additional finding of split hand/foot malformation (SHFM). We identified five consanguineous Pakistani families with either HJMD or EEM syndrome, and detected pathogenic mutations in the CDH3 gene of all five families. In order to define the role of P-cadherin in hair follicle and limb development, we performed expression studies on P-cadherin in the mouse embryo, and demonstrated the predominant expression of P-cadherin not only in the hair follicle placode, but also at the apical ectodermal ridge (AER) of the limb bud. Based on the evidence that mutations in the p63 gene also result in hypotrichosis and SHFM, and that the expression patterns of p63 and P-cadherin overlap in the hair follicle placode and AER, we postulated that CDH3 could be a direct transcriptional target gene of p63. We performed promoter assays and ChIP, which revealed that p63 directly interacts with two distinct regions of the CDH3 promoter. We conclude that P-cadherin is a newly defined transcriptional target gene of p63, with a crucial role in hair follicle morphogenesis as well as the AER during limb bud outgrowth in humans, whereas it is not required for either in mice.
--ca. 0,7 mg Fin/d, seit 06/09, KET, Salix Alba Shampoo (bei SE)--
[Abgesetzt: 1,25mg Fin (11/05-06/09), diverse NEMs]
dif. Ausdünnung am Oberkopf
|
|
|
| Thema: Association of androgenetic alopecia with smoking and its prevalence among Asian men |
|---|
| Association of androgenetic alopecia with smoking and its prevalence among Asian men [Beitrag #2381] |
Tue, 27 November 2007 01:23 |
 |
tristan
Beiträge: 42
Registriert: November 2005 |
Member |
|
|
Association of androgenetic alopecia with smoking and its prevalence among Asian men: a community-based survey.
Su LH,
Chen TH.
Department of Dermatology, Far Eastern Memorial Hospital, Taipei, Taiwan.
OBJECTIVES: To evaluate the association of androgenetic alopecia (AGA) with smoking and to estimate its prevalence among Asian men. DESIGN: Population-based cross-sectional survey. SETTING: Tainan County, Taiwan. PARTICIPANTS: The eligible population consisted of all male residents 40 years or older in Tainan County. A total of 740 subjects aged 40 to 91 years participated in the survey between April 10, 2005, and June 12, 2005. MAIN OUTCOME MEASURES: Norwood and Ludwig classifications were used to assess the degree of hair loss. Information on smoking, together with other possible risk factors and age at onset of AGA, was collected using a questionnaire interview. RESULTS: After controlling for age and family history, statistically significant positive associations were noted between moderate or severe AGA (Norwood types > or =IV) and smoking status (odds ratio [OR], 1.77; 95% confidence interval [CI], 1.14-2.76), current cigarette smoking of 20 cigarettes or more per day (OR, 2.34; 95% CI, 1.19-4.59), and smoking intensity (OR, 1.78; 95% CI, 1.03-3.07). The OR of early-onset history for AGA grades increased in a dose-response pattern. Risk for moderate or severe AGA increased for family history of first-degree and second-degree relatives, as well as for paternal relatives. CONCLUSIONS: The age-specific prevalence of AGA in Taiwan was compatible to that among Korean men but was lower than that among persons of white race/ethnicity. Smoking status, current amount of cigarette smoking, and smoking intensity were statistically significant factors responsible for AGA after controlling for age and family history. Patients with early-onset AGA should receive advice early to prevent more advanced progression.
|
|
|
| Thema: Interleukin-6 cytokine family member oncostatin M is a hair-follicle-expressed factor with hair grow |
|---|
| Interleukin-6 cytokine family member oncostatin M is a hair-follicle-expressed factor with hair grow [Beitrag #2380] |
Mon, 26 November 2007 14:41 |
|
pietrasch
Beiträge: 48
Registriert: December 2005 |
Member |
|
|
Yu M, Kissling S, Freyschmidt-Paul P, Hoffmann R, Shapiro J, McElwee KJ.
Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
The activation of receptor complexes containing glycoprotein 130 (gp130) identifies the interleukin (IL)-6 cytokine family. We examined members of this family for their expression and activity in hair follicles. Quantitative polymerase chain reaction using mRNA derived from microdissected, anagen-stage human hair follicles and comparison to non-follicular skin epithelium revealed higher levels of IL-6 (15.5-fold) and oncostatin M (OSM, 3.4-fold) in hair follicles. In contrast, expression of all mRNAs coding for IL-6 cytokine family receptors was reduced. Immunohistology suggested expression of OSM, gp130, leukaemia inhibitory factor receptor (LIFr) and IL-11r in the hair follicle root sheaths and dermal papilla, while IL-11, IL-6r and OSMr were expressed in root sheaths alone. IL-6 was expressed in the dermal papilla while cardiotrophin-1 (CT-1) and LIF were not observed. OSM and to a lesser extent CT-1 exhibited a dose-dependent growth inhibition capacity on human hair follicles in vitro. OSM and CT-1 incubated with agarose beads and injected subcutaneously at 1 mug per mouse into telogen skin of 65-day-old mice revealed no capacity to induce anagen hair growth. In contrast, injection of 65-day-old mice in which anagen had been induced by hair plucking revealed a moderate hair growth inhibitory capacity for OSM, but no significant effect for CT-1. The data identify OSM as a modulator of hair follicle growth and suggest other family members may also have some degree of hair growth inhibitory effect. In principle, increased expression of some IL-6 cytokine family members in cutaneous inflammation might contribute to the promotion of hair loss.
--ca. 0,7 mg Fin/d, seit 06/09, KET, Salix Alba Shampoo (bei SE)--
[Abgesetzt: 1,25mg Fin (11/05-06/09), diverse NEMs]
dif. Ausdünnung am Oberkopf
|
|
|
| Thema: Prostanoid receptors in anagen human hair follicles. |
|---|
| Prostanoid receptors in anagen human hair follicles. [Beitrag #2379] |
Mon, 26 November 2007 14:38 |
|
pietrasch
Beiträge: 48
Registriert: December 2005 |
Member |
|
|
Prostanoid pathway in hair follicle gained closer attention since trichogenic side-effects on hair growth has been observed concomitantly with prostaglandin F(2alpha) receptor (FP) agonist treatment of intraocular pressure. We thus investigated prostanoid receptor distribution in anagen hair follicle and different cell types from hair and skin. Using RT-PCR, Western blot and immunohistochemistry (IHC), we found that all receptors were present in hair follicle. This data shed new light on an underestimated complex network involved in hair growth control. Indeed most of these receptors showed a wide spectrum of expression in cultured cells and the whole hair follicle. Using IHC, we observed that expression of prostaglandin E(2) receptors (EP(2), EP(3), EP(4)), prostaglandin D(2) receptor (DP(2)), prostanoid thromboxane A(2) receptor (TP) and to a lesser extent EP(1) involved several hair follicle compartments. On the opposite, Prostaglandin I(2) receptor (IP) and DP(1) were more specifically expressed in hair cuticle layer and outer root sheath (ORS) basal layer, respectively. FP expression was essentially restricted to ORS companion layer and dermal papilla (DP). Although extracting a clear functional significance from this intricate network remains open challenge, FP labelling, i.e. could explain the biological effect of PGF(2alpha) on hair regrowth, by directly modulating DP function.
was sind das genau für rezeptoren und kann man sie beeinflußen??
--ca. 0,7 mg Fin/d, seit 06/09, KET, Salix Alba Shampoo (bei SE)--
[Abgesetzt: 1,25mg Fin (11/05-06/09), diverse NEMs]
dif. Ausdünnung am Oberkopf
|
|
|
| Thema: Treatment of alopecia by transplantation of hair follicle stem cells and dermal papilla cells encaps |
|---|
| Treatment of alopecia by transplantation of hair follicle stem cells and dermal papilla cells encaps [Beitrag #2341] |
Thu, 18 October 2007 19:20 |
|
pietrasch
Beiträge: 48
Registriert: December 2005 |
Member |
|
|
hat von den jungs schonml irgendwer was gehört?! wäre interessant ob sie die fsc bzw dpc vorher vervielvältigen wollen?!
Treatment of alopecia by transplantation of hair follicle stem cells and dermal papilla cells encapsulated in alginate gels.
Zhao J, Liu LQ, Wang YJ, Yang W, Geng WX, Wei J, Li LW, Chen FL.
Rege Lab of Tissue Engineering, Department of Bioscience, Faculty of Life Science, Northwest University, No. 229 North Taibai Road, Xi’an 710069, PR China.
The affected individual of hair loss demands help, because hair is viewed as a sign of youth and good health. Nowadays treatment of alopecia includes drug therapy and hair transplantation. Some drugs may promote hair growth, at least temporarily, but the treatment is effective only in milder alopecia, instead of extensive alopecia. Furthermore, the side effect of long period medication could not be avoided. Hair transplantation involves harvesting small pieces of hair-bearing scalp grafts from a donor site and relocating them to a bald area. This method does not increase the number of existing hairs, but only redistributes them. The operation is sophisticated and time-consuming, thus the patient suffers a lot during the process. The discovery of hair follicle stem cells (FSC) brings gospel to the affected individual of hair loss because of its capacity of generating new hair when they interact with mesenchymal dermal papilla cells (DPC). Besides, both FSC and DPC have strong proliferative capacity and the patient's own cells could be expanded considerably in vitro. Thus we hypothesize that the microencapsulation of the two kinds of cells in alginate gels could be implanted into the bald scalp of the patient since alginate gels is effective in cell transplantation. The strategy may provide a more convenient and valid alternative to hair loss if the hypothesis proved to be practical.
--ca. 0,7 mg Fin/d, seit 06/09, KET, Salix Alba Shampoo (bei SE)--
[Abgesetzt: 1,25mg Fin (11/05-06/09), diverse NEMs]
dif. Ausdünnung am Oberkopf
|
|
|
| Thema: freie radikale verlängern leben |
|---|
|
| Thema: von wegen cholesterol und fett sei schlecht.... |
|---|
|
| Thema: clinical trial of a novel formulation of 5% minoxidil topical foam |
|---|
 clinical trial of a novel formulation of 5% minoxidil topical foam [Beitrag #2271] |
Wed, 05 September 2007 11:02 |
 |
kkoo
Beiträge: 190
Registriert: November 2005
Ort: ausland |
Senior Member |
|
|
1: J Am Acad Dermatol. 2007 Aug 28; [Epub ahead of print]
Links
A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.
Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, Zhang P, Kohut B.
From Duke University Medical Center, Durham.
BACKGROUND: An alternative to currently marketed topical minoxidil solutions is desirable. OBJECTIVE: To assess the efficacy and safety of a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle in men with androgenetic alopecia (AGA). METHODS: This was a 16-week, double-blind, placebo-controlled trial of 5% minoxidil topical foam (MTF) in 352 men, 18 to 49 years old. At week 16, 143 subjects continued on an open-label phase to collect 52 weeks of safety information on 5% MTF. RESULTS: At week 16 compared with baseline, there was a statistically significant increase in (1) hair counts in the 5% MTF group versus placebo (P < .0001) and (2) subjective assessment of improved hair loss condition (P < .0001) in the 5% MTF group versus placebo. The 5% MTF was well tolerated over a 52-week period. LIMITATIONS: There was no collection of efficacy data beyond 16 weeks. CONCLUSIONS: We believe that 5% MTF is a safe and effective treatment for men with AGA.
- - -
Gruene Suchmaschien gefaellig? Ecosia.org ist grün.
Oekostrom? Es wird nun echt Zeit!: www.oekostrom-vergleich.com
|
|
|
| Thema: Spiegel-Artikel über Apoptose |
|---|
| Spiegel-Artikel über Apoptose [Beitrag #2270] |
Sat, 01 September 2007 11:03 |
backflash
Beiträge: 12
Registriert: January 2006 |
Junior Member |
|
|
http://www.spiegel.de/wissenschaft/mensch/0,1518,501102,00.h tml
Norwood 2, nur GHE; 1mg Fin, 2% Minox, 600mg NAC, Amino-Mix, NEM-Mix, Neril Reaktiv Haarwäsche
|
|
|
| Thema: RU 58841 - wann tut sich endlich was??? |
|---|
|
| Thema: bsp. für AR-polymorphism und reduziertes AGA-risiko |
|---|
| bsp. für AR-polymorphism und reduziertes AGA-risiko [Beitrag #2248] |
Wed, 18 July 2007 12:32 |
|
kkoo
Beiträge: 190
Registriert: November 2005
Ort: ausland |
Senior Member |
|
|
Br J Dermatol. 2007 Jun 26; [Epub ahead of print]
Men with Kennedy disease have a reduced risk of androgenetic alopecia.
Sinclair R, Greenland KJ, Egmond SV, Hoedemaker C, Chapman A, Zajac JD.
Centre for Hormone Research, Murdoch Children’s Research Institute, University of Melbourne, Royal Children’s Hospital, Parkville 3052, Victoria, Australia.
Background Spinal and bulbar muscular atrophy or Kennedy disease (KD) is an X-linked neurodegenerative disease caused by an expansion of a polymorphic tandem CAG repeat within the androgen receptor (AR) gene on chromosomal locus Xq11-q12. The CAG repeat region encodes a polyglutamine tract that, when expanded to above 40 in number, results in KD, a neurodegenerative disease primarily targeting lower motor neurones. KD is also associated with partial androgen insensitivity due to loss of receptor function. Degree of expansion of this repeat region, located in the first exon, is correlated with age at onset and disease severity. Androgenetic alopecia (AGA) is a polygenic trait also associated with functional polymorphism of the AR gene. Objectives To test whether partial loss of function in the AR gene associated with CAG polymorphism reduces the risk of AGA in affected men. Methods Members of the Kennedy's Disease Association, an American-based support group, were invited to participate in an online survey to determine the age-related prevalence of AGA among men affected by KD. Data from 115 respondents with KD were compared with data from 654 white men of European descent in Maryborough, Australia. Results The mean AGA score for men with KD was 1.64 (95% confidence interval, CI 1.41-1.87). The mean score for men in Maryborough was 2.82 (95% CI 2.71-2.93). The difference between the means was highly significant (P < 0.001), indicating thicker hair among the KD cohort. Treating AGA score as a continuous variable we found age to be highly significantly related to AGA score in men from Maryborough (P < 0.001) but not among men affected by KD (P = 0.90). Conclusions Men with KD have a reduced risk of AGA, likely to be due to a functional alteration in the AR caused by the polyglutamine expansion.
- - -
Gruene Suchmaschien gefaellig? Ecosia.org ist grün.
Oekostrom? Es wird nun echt Zeit!: www.oekostrom-vergleich.com
|
|
|
| Thema: Benzo[c]quinolizin-3-ones hemmen 5ar1... |
|---|
| Benzo[c]quinolizin-3-ones hemmen 5ar1... [Beitrag #2234] |
Mon, 02 July 2007 09:21 |
|
kkoo
Beiträge: 190
Registriert: November 2005
Ort: ausland |
Senior Member |
|
|
Benzo[c]quinolizin-3-ones: a novel class of potent and selective nonsteroidal inhibitors of human steroid 5alpha-reductase 1.
Guarna A, Machetti F, Occhiato EG, Scarpi D, Comerci A, Danza G, Mancina R, Serio M, Hardy K.
Departimento di Chimica Organica "U. Schiff" and Centro di Studio sullaChimica e la Struttura dei Composti Eterociclici e loro Applicazioni, Università di Firenze, Italy. guarna@chimorg.unifi.it
The synthesis and biological evaluation of a series of novel, selective inhibitors of isoenzyme 1 of human 5alpha-reductase (5alphaR) (EC 1.3.99.5) are reported. The inhibitors are 4aH- (19-29) or 1H-tetrahydrobenzo[c]quinolizin-3-ones (35-47) bearing at positions 1, 4, 5, and 6 a methyl group and at position 8 a hydrogen, methyl group, or chlorine atom. All these compounds were tested toward 5alphaR-1 and 5alphaR-2 expressed in CHO cells (CHO 1827 and CHO 1829, respectively) resulting in selective inhibitors of the type 1 isoenzyme, with inhibitory potencies (IC(50)) ranging from 7.6 to 9100 nM. The inhibitors of the 4aH-series, having a double bond at position 1,2, were generally less active than the corresponding inhibitors of the 1H-series having the double bond at position 4,4a on the A ring. The presence of a methyl group at position 4 (as in compounds 39-40 and 45-47), associated with a substituent at position 8, determined the highest inhibition potency (IC(50) from 7.6 to 20 nM). Compounds 39 and 40, having K(i) values of 5.8+/-1.8 and 2.7+/-0.6 nM, respectively, toward 5alphaR-1 expressed in CHO cells, were also tested toward native 5alphaR-1 in human scalp and 5alphaR-2 in human prostate homogenates, in comparison with finasteride and the known 5alphaR-1-selective inhibitor LY191704, and their mechanism of inhibition was determined. They both inhibited the enzyme through a reversible competitive mechanism and again were selective inhibitors of 5alphaR-1 with IC(50) values of 41 nM. These specific features make these inhibitors suitable candidates for further development as drugs in the treatment of DHT-dependent disorders such as acne and androgenic alopecia in men and hirsutism in women.
- - -
LY191704 inhibits type I steroid 5 alpha-reductase in human scalp.
Neubauer BL, Gray HM, Hanke CW, Hirsch KS, Hsiao KC, Jones CD, Kumar MV, Lawhorn DE, Lindzey J, McQuaid L, Tindall DJ, Toomey RE, Yao RC, Audia JE.
Lilly Research Laboratories, Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. neubauer_blake_l@lilly.com
Conversion of testosterone to dihydrotestosterone (DHT) has been demonstrated to be catalyzed by two isoforms of steroid 5 alpha-reductase, designated types I and II. Although several classes of steroid-based inhibitors of the type II isoform have been identified, these agents have not demonstrated highly selective pharmacological activity against human type I 5 alpha-reductase. LY191704 is representative of a series of nonsteroidal agents that have potent [apparent inhibitory constant (Ki) = 11.3 nM] inhibitory activity in human scalp skin homogenates (pH 7.5), a source of type I 5 alpha-reductase. [3H]-DHT production in the presence and absence of LY191704 is consistent with a noncompetitive mode of inhibition. In human prostatic homogenates (pH 5.5), a source of type II 5 alpha-reductase, LY191704 is virtually inactive as an inhibitor [concentration of inhibitor producing 50% inhibition of enzymatic activity (IC50) > 1,000 nM] of [3H]-DHT formation. LY191704 does not inhibit the type I or type II isoforms of rat 5 alpha-reductase, nor does the compound compete for binding to the murine androgen receptor expressed in SF9 cells using a baculo virus expression system. The benzoquinolinones, as exemplified by LY191704, possess exquisite pharmacological selectivity and provide a tool to understand the role of human type I 5 alpha-reductase in normal and pathophysiological states. These agents may also find clinical utility in treating androgen-dependent dermatological conditions.
- - -
Gruene Suchmaschien gefaellig? Ecosia.org ist grün.
Oekostrom? Es wird nun echt Zeit!: www.oekostrom-vergleich.com
|
|
|
| Thema: Inhibition of human hair follicle growth by endo- and exocannabinoids. |
|---|
| Inhibition of human hair follicle growth by endo- and exocannabinoids. [Beitrag #2233] |
Fri, 22 June 2007 21:49 |
|
kkoo
Beiträge: 190
Registriert: November 2005
Ort: ausland |
Senior Member |
|
|
FASEB J. 2007 Jun 12; [Epub ahead of print]
Links
Inhibition of human hair follicle growth by endo- and exocannabinoids.
Telek A, Bíró T, Bodó E, Tóth BI, Borbíró I, Kunos G, Paus R.
*Department of Physiology andCell Physiology Research Group of the Hungarian Academy of Sciences, University of Debrecen, Medical and Health Science Center, Research Center for Molecular Medicine, Debrecen, Hungary;Department of Dermatology, University Hospital Schleswig-Holstein, Campus Lübeck, University of Lübeck, Lübeck, Germany; andNational Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.
Recent studies strongly suggest that the cannabinoid system is a key player in cell growth control. Since the organ-culture of human hair follicles (HF) offers an excellent, clinically relevant model for complex tissue interaction systems, we have asked whether the cannabinoid system plays a role in hair growth control. Here, we show that human scalp HF, intriguingly, are both targets and sources of endocannabinoids. Namely, the endocannabinoid N-arachidonoylethanolamide (anandamide, AEA) as well as the exocannabinnoid Delta (9)-tetrahydrocannabinol dose-dependently inhibited hair shaft elongation and the proliferation of hair matrix keratinocytes, and induced intraepithelial apoptosis and premature HF regression (catagen). These effects were inhibited by a selective antagonist of cannabinoid receptor-1 (CB1). In contrast to CB2, CB1 was expressed in a hair cycle-dependent manner in the human HF epithelium. Since we successfully identified the presence of endocannabinoids in human HF, our data strongly suggest that human HF exploit a CB1-mediated endocannabinoid signaling system for negatively regulating their own growth. Clinically, CB1 agonists may therefore help to manage unwanted hair growth, while CB1 antagonists might counteract hair loss. Finally, human HF organ culture offers an instructive, physiologically relevant new research tool for dissecting "nonclassical" effects of endocannabinoids and their receptor-mediated signaling in general.--Telek, A., Bíró, T., Bodó, E., Tóth, B. I., Borbíró, I., Kunos, G., Paus, R. Inhibition of human hair follicle growth by endo- and exocannabinoids.
- - -
Gruene Suchmaschien gefaellig? Ecosia.org ist grün.
Oekostrom? Es wird nun echt Zeit!: www.oekostrom-vergleich.com
|
|
|
| Thema: polymeric microspheres for controlled release of finasteride |
|---|
| polymeric microspheres for controlled release of finasteride [Beitrag #2232] |
Fri, 22 June 2007 21:41 |
|
kkoo
Beiträge: 190
Registriert: November 2005
Ort: ausland |
Senior Member |
|
|
Int J Pharm. 2007 May 13; [Epub ahead of print]
Preparation of novel polymeric microspheres for controlled release of finasteride.
Peng D, Huang K, Liu Y, Liu S.
College of Chemistry and Chemical Engineering, Central South University, Changsha 410083, China.
The utility of the novel polycarbonate, poly(propylene carbonate maleate) (PPCM) to encapsulate and control the release of finasteride, via microspheres, was investigated. The PPCM microspheres loaded with finasteride were elaborated by a simple oil-in-water (O/W) emulsion-solvent evaporation method. Various manufacturing parameters, including the concentration of polymer in dichloromethane (DCM) and the polymer:finasteride ratios were altered to optimize process variables during the microspheres production. The effects of these changes on the characteristics of the microspheres were examined. The structure and morphology were characterized by wide-angle X-ray diffraction (WXRD) and scanning electron microscopy (SEM). The results showed that the mean diameter of microspheres was approximately 2mum, and had both smooth and spherical surfaces. Greater encapsulation efficiency was obtained by increasing the ratios of polymer:finasteride and the concentration of PPCM in DCM. In vitro drug release of these microcapsules was performed in a pH 7.4 phosphate-buffered solution. The release profiles of finasteride from PPCM microcapsules were found to be biphasic with a burst release followed by a gradual release phase. A prolonged in vitro drug release profile was observed. After an initial burst, a continuous drug release was observed for up to 5-6 weeks.
- - -
Gruene Suchmaschien gefaellig? Ecosia.org ist grün.
Oekostrom? Es wird nun echt Zeit!: www.oekostrom-vergleich.com
|
|
|
| Thema: ... tolerability of flutamide combined with oral contraception in moderate to severe hirsutism |
|---|
| ... tolerability of flutamide combined with oral contraception in moderate to severe hirsutism [Beitrag #2230] |
Sun, 17 June 2007 10:58 |
|
kkoo
Beiträge: 190
Registriert: November 2005
Ort: ausland |
Senior Member |
|
|
J Clin Endocrinol Metab. 2007 Jun 12; Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism. A 12-month, double-blind, parallel clinical trial.
Calaf J, López E, Millet A, Alcañiz J, Fortuny A, Vidal O, Callejo J, Escobar-Jiménez F, Torres E, Espinós JJ; the Spanish working group for hirsutism.
Department of Gynaecology, H de la Santa Creu i Sant Pau, Barcelona, Spain, Department of Gynaecology, H Virgen de la Arrixaca, Murcia, Spain Department of Gynaecology, H Clínico Universitario de Valencia, Spain, Department of Endocrinology, Clínica Puerta de Hierro, Madrid, Spain, Department of Gynaecology, H Clínic i Provincial de Barcelona, Spain, Department of Endocrinology, H Juan Canalejo, La Coruña, Spain, Department of Gynaecology, H San Joan de Déu, Barcelona, Spain, Department of Endocrinology, H Clínico de Granada, Spain.
Objective: Efficacy and tolerability of three doses of flutamide (125, 250, 375 mg) combined with a triphasic oral contraceptive (ethynylestradiol / levonorgestrel) during 12 months to treat moderate to severe hirsutism in patients with polycystic ovary syndrome (PCOS) or idiopathic hirsutism. Design: Randomized, double blind, placebo-controlled, parallel clinical trial. Patients: 131 premenopausal women, suffering from moderate to severe hirsutism were randomized to placebo or flutamide 125, 250, 375 mg daily associated with a triphasic oral contraceptive (OC) pill. Hirsutism (Ferriman-Gallwey), acne and seborrhea (Cremoncini), and hormone serum levels were monitored at baseline, 3 (except hormone serum levels), 6 and 12 months. Side effects and biochemical, haematological and hepatic parameters were assessed. Methods: Three-way analysis of variance (subject, dose, visit) with Scheffé adjustment for multiple comparisons, or non-parametrical Friedman test and Least Square Means (paired data), and Kruskall-Wallis test for unpaired data analyses. Chi-square or Fisher's test for categorical data. Results: One-hundred and nineteen patients were included in the intention to treat analysis. All flutamide doses induced a significant decrease in hirsutism, acne and seborrhea scores after 12 months compared to placebo; without differences among dose levels. Similar related side effects were observed with placebo and flutamide 125 mg (12.5%), and slightly higher with 250 mg (17.3%) and 375 mg (21.2%). No statistically significant differences were observed either among doses or compared to placebo. Conclusions: Flutamide 125 mg daily during 12 months was the minimum effective dose to diminish hirsutism in patients with polycystic ovary syndrome or with idiopathic hirsutism.
- - -
Gruene Suchmaschien gefaellig? Ecosia.org ist grün.
Oekostrom? Es wird nun echt Zeit!: www.oekostrom-vergleich.com
[Aktualisiert am: Sun, 17 June 2007 11:03] Den Beitrag einem Moderator melden |
|
|
| Thema: Allopregnenolone |
|---|
| Allopregnenolone [Beitrag #2221] |
Tue, 29 May 2007 20:14 |
|
tristan
Beiträge: 42
Registriert: November 2005 |
Member |
|
|
schon alte Kamelle
http://www.pahealthsystems.com/message35630.html
aber über Allopregnenolone kommen immer mehr Artikel.
hoffentlich bekommen wir kein Alzheimer oder Demenz von 5 AR Hemmung
Pubmed Suche:
allopregnanolone AND (brain OR finasteride OR depression OR alzheimer s OR neurodegeneration OR dementia)
3a,5a-THP = Allopregnanolone
Psychopharmacology (Berl). 2006 Jun;186(3):481-5. Epub 2005 Oct 18.
Links
3alpha,5alpha-THP: a potential plasma neurosteroid biomarker in Alzheimer's disease and perhaps non-Alzheimer's dementia.
Smith CD, Wekstein DR, Markesbery WR, Frye CA.
Department of Neurology, University of Kentucky Medical Center, Lexington, KY 40536-0098, USA. csmith@mri.uky.edu
RATIONALE: A plasma biomarker for neurodegenerative disease is desirable because blood is relatively simple to obtain compared with other biological samples such as cerebrospinal fluid. Recent literature suggests that neurosteroid metabolism may be altered in Alzheimer's disease (AD). OBJECTIVES: We sought to measure the plasma levels of seven steroids to assess their potential as biomarkers for dementia and AD. Methods: Steroids were measured using validated radioimmunoassay methods in AD (n=15), non-AD dementia (n=4), and control subjects (n=20). Demented subjects were in the mild-to-moderate stages of illness. Measurements were done blind to subject status in an independent laboratory. RESULTS: The notable finding was the significantly lower 5alpha-pregnan-3alpha-ol-20-one (3alpha,5alpha-THP) level in demented subjects compared with controls (25% decrease; p=0.004); 3alpha,5alpha-THP was the only one of the steroids demonstrating an effect of dementia. CONCLUSION: Lowered 3alpha,5alpha-THP levels appear promising as a biomarker in dementia, but further work is needed to establish the sensitivity and specificity of these findings in AD.
|
|
|
| Thema: Effect of finasteride 5 mg (Proscar) on acne and alopecia in female |
|---|
| Effect of finasteride 5 mg (Proscar) on acne and alopecia in female [Beitrag #2189] |
Mon, 07 May 2007 21:25 |
|
kkoo
Beiträge: 190
Registriert: November 2005
Ort: ausland |
Senior Member |
|
|
"Gynecol Endocrinol. 2007 Mar;23(3):142-5.
Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone.
Kohler C, Tschumi K, Bodmer C, Schneiter M, Birkhaeuser M.
Division of Gynaecological Endocrinology and Reproductive Medicine, Department Ob/Gyn, University of Berne. Berne. Switzerland.
Background. In some women with acne or alopecia who have normal serum levels of free testosterone, no clinical improvement can be reached by the classical treatment with antiandrogens, isotretinoids or corticosteroids. Our hypothesis is that some of these women have an excessive activity of the enzyme 5alpha-reductase. Objective. To evaluate the subjective benefit of the treatment with finasteride (5 mg/day) in women with normal serum levels of free testosterone suffering from acne or alopecia. Design. This was a retrospective study evaluating a questionnaire filled out by 12 patients, six of whom had acne and six of whom had alopecia. Results. Nine of the 12 patients benefited from the treatment, their symptoms decreased significantly and they felt better psychologically than before the administration of finasteride. The other three patients did not benefit at all from finasteride and reported no change in the extent of the acne/alopecia. Treatment was generally well tolerated, only a few adverse effects were noted. Conclusions. Nine of the 12 patients benefited from the treatment. This supports our hypothesis of an excessive activity of 5alpha-reductase enzyme in peripheral tissue in these patients. The fact that three of the patients did not realize any change in their symptom severity implies that there must also be other pathways in the genesis of acne and alopecia in women with normal levels of free testosterone. Further evaluation is needed to elucidate more precise indications for the administration of finasteride in women with acne and alopecia."
pubmed
- - -
Gruene Suchmaschien gefaellig? Ecosia.org ist grün.
Oekostrom? Es wird nun echt Zeit!: www.oekostrom-vergleich.com
|
|
|
| Thema: neosh101 Risiken/Parkinson - Bitte Aufklärung ! |
|---|
| neosh101 Risiken/Parkinson - Bitte Aufklärung ! [Beitrag #2178] |
Thu, 26 April 2007 08:48 |
matigol
Beiträge: 20
Registriert: July 2006 |
Junior Member |
|
|
Hallo,
in dem Thread weiter unten habe ich schon einmal nachgefragt aber die Frage ging wohl in der Masse der posts unter. Daher jetzt nochmals meine Frage zu den Risiken von neosh101:
War das mit den Symptomen der Parkinson Krankheit jetzt nur auf den Vorgänger PS1 bezogen oder gilt selbiges auch für das Produkt von Neosil???
Darf ein solches Produkt dann überhaupt auf den Markt??? Wenn es gegen 1 Leiden hilft und dabei ein viel Größeres Leiden entfachen kann????
Bitte klärt mich doch auf. Leider kann ich mit den englischen Biochemie-spezifischen Artikeln nicht viel anfangen.
Wäre schön wenn ein Experte mal Licht ins Dunkel bringen kann.
Danke
|
|
|
| Thema: Oder den hier ????? Korean doctors perform successful person-to-person hair transplant |
|---|
| Oder den hier ????? Korean doctors perform successful person-to-person hair transplant [Beitrag #2173] |
Thu, 19 April 2007 01:19 |
H_U_82
Beiträge: 23
Registriert: April 2007 |
Junior Member |
|
|
Korean doctors perform successful person-to-person hair transplant
Posted on March 6th, 2007 in Hair Transplant News by admin | 362 Views |
Doctors in Korea recently published a study on an experimental hair transplant procedure where they harvested hair grafts from one person and transplanted them into another.
The two female participants were sisters who had been involved in a previous bone marrow transplant. One of the sisters had leukemia and at the age of 14 had been donor matched with her sister who had donated bone marrow to her.
The leukemia had gone into remission, but at age 21 the bone marrow recipient had lost a lot of her hair due to chemotherapy drugs. Since the sisters were already tissue-matched for compatibility, the doctors wanted to see if they could transplant hair follicles from the one sister to the other.
The doctors first created a small clinical trial with 20 hair follicles and monitored the results by evaluating the growth at 6 months and again at 18 months.
Twenty hair grafts were removed from the back of the donor’s scalp and were transplanted into the patient’s nape of the neck. In the exact reverse of this, 20 hair grafts were removed from the back of the patient’s scalp and transplanted to the nape of her sister’s neck, the donor.
No immunosuppressive drugs were used - Immunosuppressive drugs are usually needed in organ transplants to prevent the immune system from attacking the foreign cells that have been transplanted into the donor.
The results were very encouraging. After 6 months the doctors found that 12 of the 20 hair grafts that had been transplanted to the patient’s nape had survived and were still growing. After 18th months however, only 7 grafts remained.
In her sister the results were a lot different. After 6 months only 2 hair grafts out of the 20 that were transplanted from the leukemia patient to the healthy sister had survived.
The doctors suspected that a small difference in the compatibility of the antigens (immune system triggers) might play an important role in rejecting person-to-person transplanted hair follicles and the different tolerances of the respective girl’s immune systems caused the significant differences in the survival rate of their transplanted hair follicles.
Statically speaking, the donor’s hair grafts that were transplanted to the patient showed a survival rate of 60% at 6 months and 35% at 18 months. On the other hand, the patient’s hair grafts that were transplanted to her donor sister’s neck showed a survival rate of only 10% at 6 months and 0% at 18 month.
Following the success of the small test procedure, 2,200 hair grafts were then harvested from the donor’s sister and were transplanted to the patient’s scalp. Most of the transplanted hair grafts survived, and the patient acquired a significant clinical improvement at 18 months after the hair transplantation surgery.
We believe this is only the second time it has ever been done. The first reported case was done by doctors at Ferrara University, Ferrara, Italy in 1999.
Source: Dermatologic Surgery Volume: 33 Issue 2 Page 236 - February 2007
Authors: SUNGJOO “TOMMY” HWANG MD, HYOJIN KIM MD, WEON JU LEE MD, DO WON KIM MD, JUNG CHUL KIM MD, HOON KOOK MD, JE JUNG LEE M
http://news.hairlosshelp.com/hair-transplant-news/korean-doc tors-perform-successful-person-to-person-hair-transplant/
Dut seit ca. 01.04.08
FIN 1,25 mg ca. 2 1/2 Jahre genommen
Regaine seit ca 08.01.2007
-viel viel sport, gesunde ernährung
|
|
|
| Thema: finasteride bei frauen... |
|---|
| finasteride bei frauen... [Beitrag #2147] |
Fri, 23 March 2007 21:07 |
 |
pilos
Beiträge: 170
Registriert: November 2005
Ort: Ausland |
Senior Member |
|
|
duchwachsen....
The present study involved 37 women who were treated with finasteride (2.5 mg/day) in combination with a drospirenone/ethinyl estradiol contraceptive, because finasteride has been linked to birth defects. Global photography and hair density on videodermoscopy were used to assess treatment efficacy.
After 12 months of therapy, hair growth improvements were rated as great in 3 patients, moderate in 8, slight in 12, and nonexistent in 13. In one patient, worsening of their FPHL was noted. Twelve patients showed a significant improvement in hair density (p = 0.002).
None of the patients experienced adverse effects with the treatment, the report indicates.
|
|
|
| Thema: Dutasteride improves male pattern hair loss in a randomized study in identical twins. |
|---|
| Dutasteride improves male pattern hair loss in a randomized study in identical twins. [Beitrag #2142] |
Thu, 15 March 2007 12:03 |
|
kkoo
Beiträge: 190
Registriert: November 2005
Ort: ausland |
Senior Member |
|
|
J Cosmet Dermatol. 2007 Mar;6(1):9-13.
Dutasteride improves male pattern hair loss in a randomized study in identical twins.
Stough D.
The Dermatology Clinic, Hot Springs, AR 71913, USA.
OBJECTIVES: This study compared the efficacy of dutasteride vs. placebo in the treatment of male pattern hair loss (androgenetic alopecia) in 17 pairs of identical twin males with androgenetic alopecia over a 1-year period. METHODS: In this randomized, double-blind, placebo-controlled, single-center study, one twin from each identical twin pair received dutasteride 0.5 mg/day for 12 months while the other received placebo for 12 months. Hair growth was evaluated using standardized clinical photographs, hair counts, and patient self-assessment questionnaires. RESULT: Dutasteride significantly improved hair growth at 1-year compared to placebo based on the analysis of the investigator assessment and the patient self-assessment questionnaires. Sixteen of 17 sets of twins completed the study, of which 15 sets correctly predicted the use of dutasteride. Only one set could not determine the active drug from the placebo. CONCLUSION: Through the use of identical twins, this randomized trial provides evidence that dutasteride significantly reduces hair loss progression in men with male pattern hair loss.
- - -
Gruene Suchmaschien gefaellig? Ecosia.org ist grün.
Oekostrom? Es wird nun echt Zeit!: www.oekostrom-vergleich.com
|
|
|
| Thema: zusammenhang androgen-vegf (ältere studien) |
|---|
| zusammenhang androgen-vegf (ältere studien) [Beitrag #2139] |
Sun, 11 March 2007 21:46 |
|
kkoo
Beiträge: 190
Registriert: November 2005
Ort: ausland |
Senior Member |
|
|
J Investig Dermatol Symp Proc. 1999 Dec;4(3):290-5.
In vitro main pathways of steroid action in cultured hair follicle cells: vascular approach.
Lachgar S, Charveron M, Sarraute J, Mourard M, Gall Y, Bonafe JL.
Laboratoire de Biologie Cellulaire Cutanee, Institut de Recherche Pierre Fabre, Faculte de Medecine Rangueil, Toulouse, France. souad.lachgar@pierre-fabre.com
The known role of steroids on the hair follicle leads us to investigate their effects on hair follicle cell angiogenic responses in vitro. We verified, using the immunohistochemical technique, whether human occipital scalp follicle cells express steroid receptors in vitro. We showed that androgen and estrogen receptors were expressed by dermal papilla cells (DPC) and keratinocytes from the outer root sheath in vitro. With regard to steroidal enzymes (type I and II 5alpha-reductases and Cytochrome-p-450-aromatase), the type I 5alpha-reductase gene is much more expressed in DPC than in dermal fibroblasts; however, the type II 5a-reductase gene is transcribed more in dermal fibroblasts than in DPC. The transcription of the two 5alpha-reductase isoform genes in cultured DPC is regulated by a 5alpha-reductase inhibitor. We also demonstrated that DPC, dermal fibroblasts, and outer root shealth keratinocytes expressed cytochrome-p-450-aromatase. Using ELISA and reverse transcriptase-polymerase chain reaction, we investigated the role played by some steroids (estrogens, androgens, antiandrogens) in the modulation of vascular endothelial growth factor (VEGF) expression by DPC. The association of different treatments of DPC (5alpha-reductase inhibitor and androgen receptor antagonist) shows a great stimulation of VEGF and aromatase expression. Strong stimulation of VEGF protein and gene expression is observed in the presence of 17beta-estradiol. Also, the concentration-dependent inhibition of VEGF expression by DPC using the cytochrome-p-450-aromatase inhibitor, confirms the involvement of this estrogenic pathway in the regulation of VEGF expression in vitro.
die androgenvermittelte AGA doch ein verdecktes VEGF-problem (weshalb minox auch was bringt)?
- - -
allgemein dürfte ja gelten:
J Clin Invest. 2001 Feb;107(4):409-17.
Control of hair growth and follicle size by VEGF-mediated angiogenesis.
Yano K, Brown LF, Detmar M.
Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Building 149, 13th Street, Charlestown, MA 02129, USA.
The murine hair follicle undergoes pronounced cyclic expansion and regression, leading to rapidly changing demands for its vascular support. Our study aimed to quantify the cyclic changes of perifollicular vascularization and to characterize the biological role of VEGF for hair growth, angiogenesis, and follicle cycling. We found a significant increase in perifollicular vascularization during the growth phase (anagen) of the hair cycle, followed by regression of angiogenic blood vessels during the involution (catagen) and the resting (telogen) phase. Perifollicular angiogenesis was temporally and spatially correlated with upregulation of VEGF mRNA expression by follicular keratinocytes of the outer root sheath, but not by dermal papilla cells. Transgenic overexpression of VEGF in outer root sheath keratinocytes of hair follicles strongly induced perifollicular vascularization, resulting in accelerated hair regrowth after depilation and in increased size of hair follicles and hair shafts. Conversely, systemic treatment with a neutralizing anti-VEGF antibody led to hair growth retardation and reduced hair follicle size. No effects of VEGF treatment or VEGF blockade were observed in mouse vibrissa organ cultures, which lack a functional vascular system. These results identify VEGF as a major mediator of hair follicle growth and cycling and provide the first direct evidence that improved follicle vascularization promotes hair growth and increases hair follicle and hair size.
- - -
Gruene Suchmaschien gefaellig? Ecosia.org ist grün.
Oekostrom? Es wird nun echt Zeit!: www.oekostrom-vergleich.com
[Aktualisiert am: Sun, 11 March 2007 22:03] Den Beitrag einem Moderator melden |
|
|
| Thema: Obesity and Low-Grade Inflammation among Young Finnish Men with Early-Onset Alopecia |
|---|
| Obesity and Low-Grade Inflammation among Young Finnish Men with Early-Onset Alopecia [Beitrag #2135] |
Fri, 09 March 2007 00:12 |
|
tristan
Beiträge: 42
Registriert: November 2005 |
Member |
|
|
Clinical and Laboratory Investigation
Obesity and Low-Grade Inflammation among Young Finnish Men with Early-Onset Alopecia
Päivi Hirssoa, b, Ulla Rajalaa, Liisa Hiltunena, c, Jari Jokelainena, b, Sirkka Keinänen-Kiukaanniemia, c, Simo Näyhäa
aUniversity of Oulu, Department of Public Health Science and General Practice,
bUnit of General Practice, Oulu University Hospital, and
cOulu Health Center, Oulu, Finland
http://content.karger.com/ProdukteDB/produkte.asp?Aktion=Sho wAbstract&ArtikelNr=98570&Ausgabe=232802&Produkt Nr=224164
|
|
|
| Thema: Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism. |
|---|
| Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism. [Beitrag #2132] |
Wed, 07 March 2007 18:10 |
|
kkoo
Beiträge: 190
Registriert: November 2005
Ort: ausland |
Senior Member |
|
|
"Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism.
Akdogan M, Tamer MN, Cure E, Cure MC, Koroglu BK, Delibas N.
Department of Clinical Biochemistry, School of Medicine, Suleyman Demirel University, Isparta, Turkey.
Mentha spicata Labiatae, known as spearmint and Mentha piperita Labiatae, known as peppermint can be used for various kinds of illnesses in herbal medicine and flavoring in industry. M. spicata Labiatae grows on the Anamas plateau of Yenithornarbademli town of Isparta, located in southwest part of Turkey. In this town, clinicians thought that consumption of tea steeped with M. spicata or M. piperita caused a diminished libido. Because antiandrogenic effects of spearmint and peppermint were found previously in rats, it was decided to observe the effect of this herbal tea on the androgen levels in hirsute women.Twenty-one female hirsute patients, 12 with polycystic ovary syndrome and 9 with idiopathic hirsutism were included to the study. They were took a cup of herbal tea which was steeped with M. spicata for 5 days twice a day in the follicular phase of their menstrual cycles. After treatment with spearmint teas, there was a significant decrease in free testosterone and increase in luteinizing hormone, follicle-stimulating hormone and estradiol. There were no significant decreases in total testosterone or dehydroepiandrostenedione sulphate levels. Spearmint can be an alternative to antiandrogenic treatment for mild hirsutism. Further studies are needed to test the reliability of these results and the availability of spearmint as a drug for hirsutism. Copyright (c) 2007 John Wiley & Sons, Ltd."
wenn das totale testo gleich bleibt, dann wird nur eine HSD gehemmt, und z.b. mehr T nach E2 umgesetzt ?
- - -
Gruene Suchmaschien gefaellig? Ecosia.org ist grün.
Oekostrom? Es wird nun echt Zeit!: www.oekostrom-vergleich.com
[Aktualisiert am: Wed, 07 March 2007 18:17] Den Beitrag einem Moderator melden |
|
|
| Thema: 1% minox frauen-studie, japan (nix neues...) |
|---|
| 1% minox frauen-studie, japan (nix neues...) [Beitrag #2131] |
Wed, 07 March 2007 10:19 |
|
kkoo
Beiträge: 190
Registriert: November 2005
Ort: ausland |
Senior Member |
|
|
Eur J Dermatol. 2007 Jan-Feb;17(1):37-44. Epub 2007 Feb 27.
A randomized, placebo-controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women.
Tsuboi R, Tanaka T, Nishikawa T, Ueki R, Yamada H, Katsuoka K, Ogawa H, Takeda K.
Tokyo Medical University, Department of Dermatology, Tokyo, Japan. tak-tanaka@so.taisho.co.jp.
Minoxidil is effective in inducing hair growth in patients with androgenetic alopecia by stimulating hair follicles to undergo transition from early to late anagen phase. However, there have been no controlled studies of topical minoxidil in Asian women. The objective of this trial was to investigate the efficacy of 1% topical minoxidil for androgenetic alopecia in Japanese female patients using a double-blind controlled method. This trial included 280 Japanese female patients aged 20 years or older with androgenetic alopecia who were administered either 1% topical minoxidil (n = 140) or placebo (n = 140) for 24 weeks. The primary efficacy variable was mean change from baseline in non-vellus hair count/cm(2). The mean change was 8.15 in the 1% topical minoxidil group and 2.03 in the placebo group, with a significant difference between groups (p < 0.001) [difference: 6.12 (two-sided 95% confidence interval (CI): 3.29-8.96)]. Secondary variables included investigators' assessments and patients' self-assessments. As assessed by investigators, 29.2% (40/137) of the patients had moderate or better improvement in the 1% topical minoxidil group compared to 11.8% (16/136) in the placebo group (p < 0.001 versus placebo). The effect on hair growth was assessed as improved or better by 36.5% (50/137) of the patients themselves in the 1% topical minoxidil group compared to 23.5% (32/136) in the placebo group (p = 0.019 versus placebo). The patients tolerated treatment with 1% topical minoxidil well without significant adverse effects.
quelle pubmed
edit. die wirkung vom 1% war da auch nicht grad überwältigend, muss man sagen...
- - -
Gruene Suchmaschien gefaellig? Ecosia.org ist grün.
Oekostrom? Es wird nun echt Zeit!: www.oekostrom-vergleich.com
[Aktualisiert am: Wed, 07 March 2007 15:55] Den Beitrag einem Moderator melden |
|
|
| Thema: neues vom Androgen-Rezeptor |
|---|
| neues vom Androgen-Rezeptor [Beitrag #2095] |
Fri, 02 February 2007 16:52 |
|
pietrasch
Beiträge: 48
Registriert: December 2005 |
Member |
|
|
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed& cmd=Retrieve&dopt=AbstractPlus&list_uids=17256155&am p;query_hl=8&itool=pubmed_docsum
Hum Genet. 2007 Jan 26; [Epub ahead of print]Click here to read Links
Baldness and the androgen receptor: the AR polyglycine repeat polymorphism does not confer susceptibility to androgenetic alopecia.
* Ellis JA,
* Scurrah KJ,
* Cobb JE,
* Zaloumis SG,
* Duncan AE,
* Harrap SB.
Department of Physiology, The University of Melbourne, Melbourne, VIC, 3010, Australia, justine@unimelb.edu.au.
Androgenetic alopecia, or male pattern baldness, is a complex condition with a strong heritable component. In 2001, we published the first significant evidence of a genetic association between baldness and a synonymous coding SNP (rs6152) in the androgen receptor gene, AR. Recently, this finding was replicated in three independent studies, confirming an important role for AR in the baldness phenotype. In one such replication study, it was claimed that the causative variant underlying the association was likely to be the polyglycine (GGN) repeat polymorphism, one of two apparently functional triplet repeat polymorphisms located in the exon 1 transactivating domain of the gene. Here, we extend our original association finding and present comprehensive evidence from approximately 1,200 fathers and sons drawn from 703 families of the Victorian Family Heart Study, a general population Caucasian cohort, that neither exon 1 triplet repeat polymorphism is causative in this condition. Seventy-eight percent of fathers (531/683) and 30% of sons (157/520) were affected to some degree with AGA. We utilised statistical methods appropriate for the categorical nature of the phenotype and familial structure of the cohort, and determined that whilst SNP rs6152 was strongly associated with baldness (P < 0.0001), the GGN triplet repeat was not (P = 0.13). In the absence of any other known common functional coding variants, we argue that the causative variant is likely to be in the non-coding region, and yet to be identified. The identification of functional non-coding variants surrounding AR may have significance not only for baldness, but also for the many other complex conditions that have thus far been linked to AR.
PMID: 17256155 [PubMed - as supplied by publisher]
--ca. 0,7 mg Fin/d, seit 06/09, KET, Salix Alba Shampoo (bei SE)--
[Abgesetzt: 1,25mg Fin (11/05-06/09), diverse NEMs]
dif. Ausdünnung am Oberkopf
|
|
|
| Thema: hatten wir das schonmal?! (Vitamin D) |
|---|
| hatten wir das schonmal?! (Vitamin D) [Beitrag #2092] |
Wed, 24 January 2007 09:21 |
|
pietrasch
Beiträge: 48
Registriert: December 2005 |
Member |
|
|
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed& cmd=Retrieve&dopt=AbstractPlus&list_uids=17223342&am p;query_hl=2&itool=pubmed_docsum
Role of the vitamin D receptor in hair follicle biology.
* Demay MB,
* Macdonald PN,
* Skorija K,
* Dowd DR,
* Cianferrotti L,
* Cox M.
Endocrine Unit Massachusetts General Hospital and Harvard Medical School, 50 Blossom Street, Thier 501, Boston, MA 02114, USA.
The vitamin D receptor (VDR) is expressed in numerous cells and tissues, including the skin. The critical requirement for cutaneous expression of the VDR has been proven by investigations in mice and humans lacking functional receptors. These studies demonstrate that absence of the VDR leads to the development of alopecia. The hair follicle is formed by reciprocal interactions between an epidermal placode, which gives rise to the hair follicle keratinocytes and the underlying mesoderm which gives rise to the dermal papilla. Hair follicle morphogenesis ends the second week of life in mice. Studies in VDR null mice have failed to demonstrate a cutaneous abnormality during this period of hair follicle morphogenesis. However, VDR null mice are unable to initiate a new hair cycle after the period of morphogenesis is complete, therefore, do not grow new hair. Investigations in transgenic mice have demonstrated that restricted expression of the VDR to keratinocytes is capable of preventing alopecia in the VDR null mice, thus demonstrating that the epidermal component of the hair follicle requires VDR expression to maintain normal hair follicle homeostasis. Studies were then performed to determine which regions of the VDR were required for these actions. Investigations in mice lacking the first zinc finger of the VDR have demonstrated that they express a truncated receptor containing an intact ligand binding and AF2 domain. These mice are a phenocopy of mice lacking the VDR, thus demonstrate the critical requirement of the DNA binding domain for hair follicle homeostasis. Transgenic mice expressing VDRs with mutations in either the ligand-binding domain or the AF2 domain were generated. These investigations demonstrated that mutant VDRs incapable of ligand-dependent transactivation were able to prevent alopecia. Investigations are currently underway to define the mechanism by which the unliganded VDR maintains hair follicle homeostasis.
dazu noch: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed& cmd=Retrieve&dopt=AbstractPlus&list_uids=7947199& ;query_hl=2&itool=pubmed_docsum
Hair follicle expression of 1,25-dihydroxyvitamin D3 receptors during the murine hair cycle.
* Reichrath J,
* Schilli M,
* Kerber A,
* Bahmer FA,
* Czarnetzki BM,
* Paus R.
Department of Dermatology, Universitat des Saarlandes, Homburg, Germany.
Because the hair follicle is a highly hormone-sensitive miniorgan, the role of hormones produced locally in the skin in the control of hair growth deserves systematic analysis. It has been shown previously that the potent steroid hormone 1,25-dihydroxyvitamin D3 (1,25-D3) modulates growth and differentiation of keratinocytes via binding to a high-affinity nuclear vitamin D receptor (VDR). In this study, we have examined the in situ expression of VDR during the murine hair cycle. VDR expression was detected immunohistochemically. To obtain defined stages of the murine hair cycle, hair growth was induced by depilation in C57 BL-6 mice. In addition to the recognized VDR expression of outer root sheath keratinocytes, we detected VDR immunoreactive cells in the dermal papilla, the mesenchymal key structure of the hair follicle. Furthermore, VDR immunoreactivity in the nuclei of outer root sheath keratinocytes and in dermal papilla cells was stronger during anagen IV-VI and catagen than during telogen and anagen I-III. This suggests hair cycle-associated changes in the expression of VDR, and points to a potential role for 1,25-D3 in hair follicle biology. Selected follicular cell populations may display hair cycle-dependent sensitivity to 1,25-D3 stimulation.
--ca. 0,7 mg Fin/d, seit 06/09, KET, Salix Alba Shampoo (bei SE)--
[Abgesetzt: 1,25mg Fin (11/05-06/09), diverse NEMs]
dif. Ausdünnung am Oberkopf
|
|
|
| Thema: für die polymorphismus-theoretiker |
|---|
| für die polymorphismus-theoretiker [Beitrag #2087] |
Sat, 20 January 2007 00:03 |
|
kkoo
Beiträge: 190
Registriert: November 2005
Ort: ausland |
Senior Member |
|
|
zitat:
"5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
Hayes VM, Severi G, Padilla EJ, Morris HA, Tilley WD, Southey MC, English DR, Sutherland RL, Hopper JL, Boyle P, Giles GG.
Cancer Research Program, Garvan Institute of Medical Research, St Vincent's Hospital, Sydney, Australia.
Controversy exists over the significance of associations between the SRD5A2 (5alpha-reductase type 2) polymorphisms, A49T and V89L, and risk of prostate cancer. These potentially functional polymorphisms may alter life-long exposure to androgens with subsequent effects on male health and aging. The aim of this study was to examine the association of these variants with prostate cancer risk, plasma hormone levels and androgenetic alopecia. Subjects include 827 cases and 736 controls from an Australian population-based case-control study of prostate cancer. Information on prostate cancer risk factors and patterns of balding were collected. Plasma levels of testosterone, 3alpha-diol glucuronide (3alpha-diolG), dehydroepiandrosterone sulfate, androstenedione, sex hormone-binding globulin and estradiol were measured for controls. No associations with the V89L polymorphism were found. Carriers of the rarer A49T A allele were at a 60% higher risk of prostate cancer (OR = 1.60; 95% CI 1.09-2.36; p = 0.02) and 50% lower risk of vertex and frontal balding (p = 0.03) compared with men homozygous for the more common G allele. Although we found little evidence of association between this variant and plasma levels of 5 measured androgens, circulating 3alpha-diolG levels were 34% lower in A49T A allele carriers (p < 0.0001). Our study provides evidence that the SRD5A2 A49T A variant is associated with an increased risk of prostate cancer, lower levels of circulating 3alpha-diolG and decreased risk of baldness. These findings raise important questions with respect to previous assumptions concerning hormonal influences on prostate cancer risk in ageing males. (c) 2006 Wiley-Liss, Inc."
quelle pubmed
- - -
Gruene Suchmaschien gefaellig? Ecosia.org ist grün.
Oekostrom? Es wird nun echt Zeit!: www.oekostrom-vergleich.com
|
|
|
| Thema: "Treatment of female pattern hair" |
|---|
| "Treatment of female pattern hair" [Beitrag #2086] |
Fri, 19 January 2007 23:58 |
|
kkoo
Beiträge: 190
Registriert: November 2005
Ort: ausland |
Senior Member |
|
|
nur case-study, aber dennoch:
zitat:
"Treatment of female pattern hair loss with a combination of spironolactone and minoxidil.
Hoedemaker C, van Egmond S, Sinclair R.
Department of Dermatology, St Vincent's Hospital, University of Melbourne, and Department of Medicine and Skin and Cancer Foundation, Melbourne, Victoria, Australia.
A 53-year-old woman with clinical evidence of female pattern hair loss and histological evidence of androgenetic alopecia was initially treated with the oral antiandrogen spironolactone 200 mg daily. Serial scalp photography documented hair regrowth at 12 months; however, the hair regrowth plateaued, and at 24 months there had been no further improvement in hair density. Twice daily therapy with topical minoxidil 5% solution was then introduced and further regrowth documented, confirming the additive effect of combination therapy."
quelle pubmed
- - -
Gruene Suchmaschien gefaellig? Ecosia.org ist grün.
Oekostrom? Es wird nun echt Zeit!: www.oekostrom-vergleich.com
|
|
|
| Thema: gewebe- und serum-dht-suppr. durch dut. |
|---|
| gewebe- und serum-dht-suppr. durch dut. [Beitrag #2085] |
Fri, 19 January 2007 23:53 |
|
kkoo
Beiträge: 190
Registriert: November 2005
Ort: ausland |
Senior Member |
|
|
ist zwar nicht kopfhaut, sondern prostata, aber dennoch: die serumsuppr.korreliert mit der gewebe-suppr.! sehr interessant auch die testo-beobachtung:
zitat:
"The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R.
1Department of Urology, Grove Hill Medical Center, New Britain, CT, USA.
The dual 5alpha-reductase inhibitor, dutasteride has been shown to suppress serum dihydrotestosterone (DHT) by >90%. In the present study, the effect of dutasteride 0.5 mg/day on intraprostatic DHT levels was investigated. In this multicenter, double-blind trial, 43 men with benign prostatic hyperplasia (BPH) scheduled to undergo transurethral resection of the prostate (TURP) were randomized to receive dutasteride, 0.5 mg/day or placebo for 3 months before surgery. Intraprostatic DHT, testosterone and dutasteride levels were determined at the time of TURP. Changes in serum DHT and testosterone from baseline, and both serum and intraprostatic dutasteride levels at the time of TURP were also assessed. Dutasteride reduced intraprostatic DHT by 94% relative to placebo (P<0.001); the adjusted mean intraprostatic DHT concentration was 3.23 and 0.209 ng/g in the placebo and dutasteride groups, respectively. In the dutasteride group, serum DHT was reduced from baseline by 93% at month 3, a significantly greater reduction (P<0.001) than the 15% decrease observed in the placebo group. There was a reciprocal increase in intraprostatic testosterone but the level of intraprostatic testosterone in the dutasteride group tended to be lower than the intraprostatic DHT level in the placebo group (P=0.06). Significant intraprostatic DHT suppression was achieved in all subjects who received dutasteride, regardless of the level of intraprostatic dutasteride. There was a strong positive correlation between serum and intraprostatic dutasteride concentrations (R(2)=0.73). After 3 months of treatment, dutasteride 0.5 mg/day provided near-complete suppression of both intraprostatic and serum DHT in men with BPH.Prostate Cancer and Prostatic Diseases advance online publication, 26 December 2006; doi:10.1038/sj.pcan.4500931."
quelle pubemd
- - -
Gruene Suchmaschien gefaellig? Ecosia.org ist grün.
Oekostrom? Es wird nun echt Zeit!: www.oekostrom-vergleich.com
[Aktualisiert am: Fri, 19 January 2007 23:54] Den Beitrag einem Moderator melden |
|
|
| Thema: liposomal finasteride |
|---|
| liposomal finasteride [Beitrag #2074] |
Thu, 11 January 2007 13:44 |
Alex1
Beiträge: 21
Registriert: January 2006 |
Junior Member |
|
|
Finasteride is indicated orally in the treatment of androgenetic alopecia and some other pilosebaceous unit (PSU) disorders. We wished to investigate whether topical application of finasteride-containing vesicles (liposomes and niosomes) could enhance drug concentration at the PSU, as compared to finasteride hydroalcoholic solution (HA). Liposomes consisted of phospholipid (dimyristoyl phosphatidylcholine (DMPC) or egg lecithin):cholesterol:dicetylphosphate (8:2:1, mole ratio). Niosomes were comprising non-ionic surfactant (polyoxyethylene alkyl ethers (Brij series) or sorbitan monopalmitate):cholesterol:dicetylphosphate (7:3:1, mole ratio). Vesicles were prepared by the film hydration technique and characterized with regard to the size, drug entrapment efficiency and gel-liquid transition temperature (T(c)). In vitro permeation of (3)H-finasteride through hamster flank skin was faster from hydroalcoholic solution (0.13 microg/cm(2)h) compared to vesicles (0.025-0.058 microg/cm(2)h). In vivo deposition of (3)H-finasteride vesicles in hamster ear showed that liquid-state vesicle, i.e. those made of DMPC or Brij97:Brij76 (1:1), were able to deposit 2.1 or 2.3% of the applied dose to the PSU, respectively. This was significantly higher than drug deposition by gel-state vesicles (0.35-0.51%) or HA (0.76%). Both in vitro permeation and in vivo deposition studies, demonstrated the potentials of liquid-state liposomes and niosomes for successful delivery of finasteride to the PSU.
PMID: 16837150 [PubMed - indexed for MEDLINE]
|
|
|
| Thema: NEOSH101 |
|---|
|
| Thema: minox+retinol-studie (wenig neues wohl...) |
|---|
| minox+retinol-studie (wenig neues wohl...) [Beitrag #2069] |
Fri, 05 January 2007 13:12 |
|
kkoo
Beiträge: 190
Registriert: November 2005
Ort: ausland |
Senior Member |
|
|
zitat:
"Biol Pharm Bull. 2007 Jan;30(1):21-6.
The additive effects of minoxidil and retinol on human hair growth in vitro.
Yoo HG, Chang IY, Pyo HK, Kang YJ, Lee SH, Kwon OS, Cho KH, Eun HC, Kim KH.
Department of Dermatology, Seoul National University College of Medicine, Laboratory of Cutaneous Aging and Hair Research, Clinical Research Institute, Seoul National University Hospital, Institute of Dermatological Science, Seoul National University.
Minoxidil enhances hair growth by prolonging the anagen phase and induces new hair growth in androgenetic alopecia (AGA), whereas retinol significantly improves scalp skin condition and promotes hair growth. We investigated the combined effects of minoxidil and retinol on human hair growth in vitro and on cultured human dermal papilla cells (DPCs) and epidermal keratinocytes (HaCaT). The combination of minoxidil and retinol additively promoted hair growth in hair follicle organ cultures. In addition, minoxidil plus retinol more effectively elevated phosphorylated Erk, phosphorylated Akt levels, and the Bcl-2/Bax ratio than minoxidil alone in DPCs and HaCaT. We found that the significant hair shaft elongation demonstrated after minoxidil plus retinol treatment would depend on the dual kinetics associated with the activations of Erk- and Akt-dependent pathways and the prevention of apoptosis by increasing the Bcl-2/Bax ratio."
quelle pubmed
|
|
|
| Thema: Sylvester Thread |
|---|
| Sylvester Thread [Beitrag #2068] |
Sun, 31 December 2006 16:06 |
 |
Quick
Beiträge: 30
Registriert: November 2005 |
Member |
|
|
0,5mg Avo(stopped since 2.8.06),NEM, since 16.8.06 1,25mg finasterid, 50ug T4, Rogaine 2%,
He-MaaaaaaaaaaaaaaaaaaaaaaN 
Et es wie et es, et kütt wie et kütt, und et hätt noch immer jot jejange 
|
|
|
| Thema: HIER LESEN! |
|---|
 HIER LESEN! [Beitrag #2067] |
Sun, 31 December 2006 05:39 |
 |
FrankfurtER-1974
Beiträge: 2
Registriert: November 2005 |
Junior Member |
|
|
Hallo zusammen,
der Admin space007 hat bereits geschrieben, dass Neuanmeldungen von Usern durch einige Vorfälle bis auf weiteres durch einen Administratoren freigeschaltet werden müssen.
Da wir uns hier durch eine Welle von SPAM überrollt sehen, müssen wir weitere Einschränkungen setzen, die auch schon seitens eines Admins eingeläutet wurden:
1. Zwischen dem Absenden von zwei Beiträgen muss nun eine Zeit von mindestens 120 Sekunden liegen.
2. "Mona" und "glockenspiel" erhalten für die nächsten Tage Moderatorenrechte in allen Foren mitsamt Unterforen, um schneller eingreifen zu können.
Ich erwähne es nur recht ungern, aber ich bin *ausgesprochen ungehalten*, was hier heute abgelaufen ist! Es ist nicht sonderlich lustig, wenn man im Urlaub um vier Uhr nachts per SMS von irgendwelchen Problemen im Forum erfährt und sich dann noch mit einem technischen Admin besprechen muss, der sich dann wiederum die Nacht um die Ohren schlägt, um diverse Schritte umzusetzen.
Wir haben intern eine klare Absprache getroffen: Sollte hier jemand noch einmal durch SPAM auffällig werden, wird diese Person *sofort* und ohne weitere Vorwarnung bis auf weiteres gesperrt!
Wer meint, hier geistreiche Smily-Beiträge oder anderen Spam verfassen und anderen die Nacht, den Schlaf und den Urlaub vermiesen zu müssen, der kann in den nächsten Tagen in einem anderen Forum spammen oder mit einem Bleistift auf einem Stück Papier Smilies malen...
Grüße vom
FrankfurtER
[Aktualisiert am: Tue, 16 January 2007 00:56] Den Beitrag einem Moderator melden |
|
|
Mitglieder
Suche
Hilfe
Registrieren
Anmelden
Startseite
Professional Partner